Literature DB >> 19750567

Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009.

Murad Aljiffry1, Mark J Walsh, Michele Molinari.   

Abstract

Several advances in diagnosis, treatment and palliation of cholangiocarcinoma (CC) have occurred in the last decades. A multidisciplinary approach to this disease is therefore recommended. CC is a relatively rare tumor and the main risk factors are: chronic inflammation, genetic predisposition and congenital abnormalities of the biliary tree. While the incidence of intra-hepatic CC is increasing, the incidence of extra-hepatic CC is trending down. The only curative treatment for CC is surgical resection with negative margins. Liver transplantation has been proposed only for selected patients with hilar CC that cannot be resected who have no metastatic disease after a period of neoadjuvant chemo-radiation therapy. Magnetic resonance imaging/magnetic resonance cholangiopancreatography, positron emission tomography scan, endoscopic ultrasound and computed tomography scans are the most frequently used modalities for diagnosis and tumor staging. Adjuvant therapy, palliative chemotherapy and radiotherapy have been relatively ineffective for inoperable CC. For most of these patients biliary stenting provides effective palliation. Photodynamic therapy is an emerging palliative treatment that seems to provide pain relief, improve biliary patency and increase survival. The clinical utility of other emerging therapies such as transarterial chemoembolization, hepatic arterial chemoinfusion and high intensity intraductal ultrasound needs further study.

Entities:  

Mesh:

Year:  2009        PMID: 19750567      PMCID: PMC2744180          DOI: 10.3748/wjg.15.4240

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  299 in total

Review 1.  Imaging of intrahepatic and hilar cholangiocarcinoma.

Authors:  B I Choi; J M Lee; J K Han
Journal:  Abdom Imaging       Date:  2004-06-08

Review 2.  Pathology of cholangiocarcinoma.

Authors:  J H Lim; C K Park
Journal:  Abdom Imaging       Date:  2004-06-23

3.  A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures.

Authors:  Benjamin R Kipp; Linda M Stadheim; Shari A Halling; Nicole L Pochron; Scott Harmsen; David M Nagorney; Thomas J Sebo; Terry M Therneau; Gregory J Gores; Piet C de Groen; Todd H Baron; Michael J Levy; Kevin C Halling; Lewis R Roberts
Journal:  Am J Gastroenterol       Date:  2004-09       Impact factor: 10.864

4.  Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study.

Authors:  T André; C Tournigand; O Rosmorduc; S Provent; F Maindrault-Goebel; D Avenin; F Selle; F Paye; L Hannoun; S Houry; B Gayet; J P Lotz; A de Gramont; C Louvet
Journal:  Ann Oncol       Date:  2004-09       Impact factor: 32.976

Review 5.  Endoscopic management of cholangiocarcinoma.

Authors:  Emad M Abu-Hamda; Todd H Baron
Journal:  Semin Liver Dis       Date:  2004-05       Impact factor: 6.115

Review 6.  Surgical management of cholangiocarcinoma.

Authors:  William R Jarnagin; Margo Shoup
Journal:  Semin Liver Dis       Date:  2004-05       Impact factor: 6.115

7.  Liver transplantation for unresectable perihilar cholangiocarcinoma.

Authors:  Julie K Heimbach; Gregory J Gores; Michael G Haddock; Steven R Alberts; Scott L Nyberg; Michael B Ishitani; Charles B Rosen
Journal:  Semin Liver Dis       Date:  2004-05       Impact factor: 6.115

8.  Relief of jaundice by external beam radiotherapy and intraluminal brachytherapy in patients with extrahepatic cholangiocarcinoma: results without stenting.

Authors:  Hiroshi Ishii; Junji Furuse; Michitaka Nagase; Mitsuhiko Kawashima; Hiroshi Ikeda; Masahiro Yoshino
Journal:  Hepatogastroenterology       Date:  2004 Jul-Aug

9.  Prospective, blinded assessment of factors influencing the accuracy of biliary cytology interpretation.

Authors:  Gavin C Harewood; Todd H Baron; Linda M Stadheim; Benjamin R Kipp; Thomas J Sebo; Diva R Salomao
Journal:  Am J Gastroenterol       Date:  2004-08       Impact factor: 10.864

Review 10.  A review and update on cholangiocarcinoma.

Authors:  Matthew J Olnes; Rodrigo Erlich
Journal:  Oncology       Date:  2004       Impact factor: 2.935

View more
  92 in total

1.  Brain metastasis and leptomeningeal carcinomatosis in a patient with cholangiocarcinoma.

Authors:  Basem M William; Jean L Grem
Journal:  Gastrointest Cancer Res       Date:  2011-07

2.  Lymphovascular and perineural invasion as selection criteria for adjuvant therapy in intrahepatic cholangiocarcinoma: a multi-institution analysis.

Authors:  Sarah B Fisher; Sameer H Patel; David A Kooby; Sharon Weber; Mark Bloomston; Clifford Cho; Ioannis Hatzaras; Carl Schmidt; Emily Winslow; Charles A Staley; Shishir K Maithel
Journal:  HPB (Oxford)       Date:  2012-05-22       Impact factor: 3.647

Review 3.  Imaging and interventions in hilar cholangiocarcinoma: A review.

Authors:  Kumble Seetharama Madhusudhan; Shivanand Gamanagatti; Arun Kumar Gupta
Journal:  World J Radiol       Date:  2015-02-28

4.  Recurrent Cholangiocarcinoma Presenting as Sister Mary Joseph Nodule After Liver Transplantation.

Authors:  Vijayadershan Muppidi; Sreenath Meegada; James D Eason; Satheesh P Nair; Rajanshu Verma
Journal:  Cureus       Date:  2020-11-24

5.  Reappraisal of hepatopancreatoduodenectomy as a treatment modality for bile duct and gallbladder cancer.

Authors:  Chang-Sup Lim; Jin-Young Jang; Seung Eun Lee; Mee Joo Kang; Sun-Whe Kim
Journal:  J Gastrointest Surg       Date:  2012-01-24       Impact factor: 3.452

Review 6.  Progression of targeted therapy in advanced cholangiocarcinoma.

Authors:  Yingying Huang; Xiaomei Li; Yunbo Zhao
Journal:  Chin J Cancer Res       Date:  2015-04       Impact factor: 5.087

Review 7.  Magnetic resonance evaluations of biliary malignancy and condition at high-risk for biliary malignancy: Current status.

Authors:  Reiji Sugita
Journal:  World J Hepatol       Date:  2013-12-27

8.  A differential microRNA profile distinguishes cholangiocarcinoma from pancreatic adenocarcinoma.

Authors:  Amy L Collins; Sylwia Wojcik; James Liu; Wendy L Frankel; Hansjuerg Alder; Lianbo Yu; Thomas D Schmittgen; Carlo M Croce; Mark Bloomston
Journal:  Ann Surg Oncol       Date:  2013-09-18       Impact factor: 5.344

9.  Cytopathologic diagnosis of liver mass lesions.

Authors:  Rachel Conrad; Shobha Castelino-Prabhu; Camilla Cobb; Anwar Raza
Journal:  J Gastrointest Oncol       Date:  2013-03

10.  MicroRNAs in Cholangiopathies.

Authors:  Steven P O'Hara; Sergio A Gradilone; Tetyana V Masyuk; James H Tabibian; Nicholas F LaRusso
Journal:  Curr Pathobiol Rep       Date:  2014-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.